Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13654294 | 0.80 | LTA4H (0.38) | HTTEPHX2EPHX1ALDH1A1NPC1 | |
| SCHEMBL18559452 | 0.80 | HTT (0.36) | HTTEPHX2EPHX1ALDH1A1NPC1 | |
| SCHEMBL12425051 | 0.80 | EPHX1 (0.37) | HTTEPHX2EPHX1ALDH1A1NPC1 | |
| SCHEMBL13654292 | 0.78 | ATM (0.44) | EPHX2EPHX1ALDH1A1KDM4E | |
| SCHEMBL19457387 | 0.78 | KDM4E (0.43) | EPHX2EPHX1ALDH1A1KDM4E | |
| SCHEMBL19501195 | 0.78 | HTT (0.35) | HTTEPHX2EPHX1ALDH1A1NPC1 | |
| SCHEMBL14303156 | 0.78 | — | — | |
| SCHEMBL13654274 | 0.77 | POLB (0.53) | HTTEPHX2ALDH1A1RAB9ACYP3A4 | |
| SCHEMBL23173205 | 0.75 | SIGMAR1 (0.38) | EPHX2EPHX1ALDH1A1CYP3A4 | |
| SCHEMBL21882358 | 0.75 | EPHX2 (0.34) | HTTEPHX2EPHX1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166942-B2 | Inhibitors of integrated stress response pathway | Praxis Biotech LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166942-B2 | Inhibitors of integrated stress response pathway | ATF4, DDIT3, ATF1 | HTT 3889/4885EPHX2 4001/4885EPHX1 4173/4885 |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | HTT 3889/4885EPHX2 4001/4885EPHX1 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.